Clinical trial NCT03264950: Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients
Official title: The Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric Cystic Fibrosis Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cystic Fibrosis
Cystic Fibrosis Liver Disease
Pancreatic Insufficiency Due to Cystic Fibrosis of Pancreas
Lead sponsor: University of Manitoba
Sponsor class: OTHER
First posted: 2017-08-29
Enrollment: 60
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients (\<18 years) will be recruited from from the Children's Hospital Winnipeg CF clinic. Charts will be reviewed for demographic and clinical data including blood work. Each patient will undergo shear wave elastography by a trained operator.
Primary purpose: DIAGNOSTIC

Brief summary: Diagnosis of hepatic fibrosis is challenging as specific tests for detection of fibrosis in pediatric Cystic Fibrosis associated liver disease (CFALD) have not been developed and existing investigations do not correlate well with presence or severity of disease. Using a Liver biopsy it is difficult to diagnose this condition because of the patchy nature of the disease. Investigators intend to identify hepatic and pancreatic fibrosis in Cystic Fibrosis patients using Elastography and correlate this with their biochemical markers as well as histological findings of patients who have undergone liver biopsy for diagnosis of CFALD.

Detailed description: Liver disease is increasingly common in cystic fibrosis (CF). As new therapeutic options emerge, life expectancy increases and common hepatobiliary manifestations impact on quality of life and survival of CF patients. Hepatobiliary abnormalities in CF vary in nature and range from defects attributable to the underlying CFTR gene defect to those related to systemic disease and malnutrition. Today complications of liver disease represent the third most frequent cause of disease-related death in patients with CF.

Cystic fibrosis-associated liver disease (CFALD) belongs to the group of common symptoms of this disease; however, due to the lack of specific and sensitive CFALD diagnostic markers, the epidemiological data may be incomplete. According to various sources, the prevalence rate of CFALD, diagnosed on the basis of clinical, biochemical and imaging (ultrasonography) tests, is 2-37% in children and young adults.

Cirrhosis is a final, irreversible stage of liver damage that leads to the failure of the organ. While liver biopsy is considered the gold standard to assess for Hepatic Fibrosis; it is invasive and potentially life threatening. The prognosis and management of chronic liver disease depends on the extent and progression of liver fibrosis, which constitutes the most important predictor of disease outcome.

The gold standard for diagnosis and staging of liver fibrosis has been liver biopsy. In addition to being an invasive procedure with potential complications of bleeding and severe pain, sampling error is an intrinsic problem due to the small sample size in a heterogeneous process.7,8 Inter-observer variability also limits diagnostic consistency.9-11 The development of several blood markers such as platelets, hyaluronic acid, type IV collagen, aminotransferase/platelet ratio index (APRI) and algorithm based serum models (Fibro Index, FIB-4, and Fibro Test) have been used but are affected by factors unrelated to the liver.

In the last decade, methods to noninvasively quantify liver fibrosis have been developed. The first available method was transient elastography (TE).It is a single-element ultrasound transducer operating at 5 MHz built on the axis of a piston like vibrator. By pushing a button, low-frequency (50 Hz) transient vibrations are transmitted, and the generated elastic shear waves propagate through underlying tissues. Pulse-echo ultrasound acquisitions are used to follow the propagation of the shear wave and to measure its velocity .

Several studies have demonstrated a high accuracy of TE in identifying significant fibrosis (F\> 2) and cirrhosis (F= 4) in patients. It is a novel diagnostic tool that offers a rapid, non-invasive method for monitoring HF. The device measures liver stiffness by transmitting a vibration to determine the velocity of an elastic shear wave propagated through liver tissue.

Studies have documented utility of transient elastography in cystic fibrosis patients to assess hepatic fibrosis and secondary complications.

Newer modalities like Shear wave elastography techniques have been implemented in conventional real-time ultrasound systems, and several studies have shown their accuracy in the assessment of liver fibrosis. Shear wave elastography relies on the generation of shear waves determined by the displacement of tissues induced by the force of a focused ultrasound beam or by external pressure. The shear waves are lateral waves, with a motion perpendicular to the direction of the force that has generated them. They travel slowly (between 1 and 10 m/s) and are rapidly attenuated by tissue. The propagation velocity of the shear waves correlates with the elasticity of tissue .

Compared with TE, these techniques have the advantage of B-mode image guidance; thus, they can allow the user to choose the best acoustic window for correctly performing an examination in real time.

Eligibility criteria: Inclusion Criteria:

* Age \<18 years
* Confirmed diagnosis of cystic fibrosis attending Pediatric cystic fibrosis (CF) Clinic at Children's Hospital, Winnipeg.

Exclusion Criteria:

* Children with age \>18 years

Primary outcomes:
measure: Evaluate the diagnostic properties of Shear wave Elastography
timeFrame: 6 months
Secondary outcomes:
measure: To compare findings/fibrosis of Transient Elastography vs ElastPQ
timeFrame: 6 months
measure: To compare the pancreatic insufficiency/ fecal elastase and transient elastography from pancreas.
timeFrame: 6 months
Other outcomes:
Locations:
city: Winnipeg
country: Canada
facility: Winnipeg Children's Hospital
state: Manitoba
Study officials:
affiliation: University of Manitoba
name: Quais Mujawar
role: PRINCIPAL_INVESTIGATOR
References: